文献速递焦虑、强迫与应激相关障碍会诊联络精神医学

初级保健中PTSD药物治疗与聚焦创伤心理治疗的实效性随机对照试验

Pragmatic Comparative Effectiveness of Primary Care Treatments for Posttraumatic Stress Disorder: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2025-01-01

该实效性随机试验纳入700例初级保健PTSD患者,比较SSRI、WET及序贯策略。4个月时SSRI与WET组PCL-5降幅无显著组间差异。对SSRI无应答者,换用SNRI的PCL-5降幅显著大于WET增效。

要点

  • 初级保健中SSRI与WET治疗PTSD均可行且有效,4个月PCL-5降幅无显著差异。
  • SSRI无应答者换用SNRI的PCL-5降幅显著优于WET增效。
  • 试验为实效性设计,疗效依赖治疗参与度和治疗保真度。

核心结论

  • 初级保健中SSRI或WET治疗PTSD均可行且有效,两者4个月PCL-5降幅无显著组间差异。
  • 对SSRI无应答者,换用SNRI可能比WET增效更有效。

研究设计与样本

  • 实效性比较效果随机临床试验,2021年4月至2024年6月纳入7家联邦合格健康中心和8家退伍军人事务医疗中心初级保健诊所的PTSD患者。
  • 共纳入700例符合PTSD临床标准的患者,随机分配至SSRI后WET增效、SSRI后换用SNRI或WET后SSRI三种治疗序列。

主要发现

  • 700例患者平均(SD)年龄45.1(15.4)岁,其中男性368例(62.1%)。
  • 基线PCL-5平均(SD)评分为52.8(11.1),提示症状严重程度较高。
  • 4个月时,SSRI组278例中144例(51.8%)依从并报告PCL-5降低14.0分,WET组352例中111例(31.5%)完成全部治疗并报告PCL-5降低12.1分。

关键数值与推荐

  • 主要结局为DSM-5 PTSD检查表(PCL-5)评估的PTSD症状严重程度。

临床怎么用

  • 初级保健中可考虑SSRI或WET作为PTSD初始治疗,两者均可行且有效。
  • 对SSRI无应答的PTSD患者,换用SNRI可能比WET增效更有效。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There have only been 3 efficacy trials reporting head-to-head comparisons of pharmacotherapy and trauma-focused psychotherapy for posttraumatic stress disorder (PTSD), and none were conducted in primary care. In addition, few trials have examined treatment sequences for patients not responding to an initial treatment. OBJECTIVE: To test the hypothesis that (1) brief trauma-focused psychotherapy (written exposure therapy [WET]) is more effective than a choice of 3 selective serotonin reuptake inhibitors (SSRIs; ie, sertraline, fluoxetine, or paroxetine) and (2) WET augmentation is more effective than switching to the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine for those not responding to an SSRI. DESIGN, SETTING, AND PARTICIPANTS: This was a pragmatic comparative effectiveness trial conducted from April 2021 to June 2024 that randomized primary care patients to 1 of 3 treatment sequences: (1) SSRI followed by WET augmentation, (2) SSRI followed by switch to SNRI, or (3) WET followed by SSRI. Effectiveness in this pragmatic trial depends on treatment engagement and treatment fidelity. The study included patients meeting clinical criteria for PTSD from primary care clinics of 7 federally qualified health centers and 8 Department of Veterans Affairs medical centers. INTERVENTIONS: SSRI followed by WET augmentation, SSRI followed by switch to SNRI, or WET followed by SSRI. MAIN OUTCOMES AND MEASURES: PTSD symptom severity, as measured by the DSM-5 PTSD Checklist (PCL-5). RESULTS: A total of 700 patients (mean [SD] age, 45.1 [15.4] years; 368 men [62.1%]). The mean (SD) baseline PCL-5 score was 52.8 (11.1), indicating considerable symptom severity. At 4 months, 144 of 278 patients (51.8%) randomized to an SSRI were adherent and reported a 14.0-point PCL-5 decrease, whereas 111 of 352 patients (31.5%) randomized to WET completed all sessions and reported a 12.1-point decrease. There was no significant between-group difference (adjusted mean difference [MD], 1.79; 95% CI, -0.76 to 4.34; P = .17). For the 122 of 295 patients (41.4%) randomized to an SSRI who did not respond to treatment, those randomized to switch to the SNRI reported a 9.2-point PCL-5 decrease compared with a 2.3-point decrease for those randomized to WET augmentation, which was a statistically significant between-group difference (adjusted MD, 10.19; 95% CI, 4.97-15.41; P < .001). CONCLUSIONS AND RELEVANCE: Study results showed that treatment of PTSD in primary care with either SSRIs or WET was feasible and effective. For patients not responding to an SSRI, switching to an SNRI may be more effective than WET augmentation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04597190.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fortney JC, Kaysen DL, Engel CC, et al. Pragmatic Comparative Effectiveness of Primary Care Treatments for Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025. PMID: 41091477. doi:10.1001/jamapsychiatry.2025.2962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。